Skip to main content

Appili Therapeutics Inc. (APLIF)

New York Stock Exchange Healthcare BiotechnologyView data quality →
37.1Poor

ValueMarkers Composite Index

Top 3%#43,292 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-10.00
Low Risk
Altman
-38.24
Distress
DCF Value
-
N/A
ROIC
79.8%
Strong
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Appili Therapeutics Inc. (APLIF) — VMCI valuation read

Appili Therapeutics Inc. (APLIF) carries a VMCI composite of 37/100, 13 points below the Healthcare sector median of 50. Among mid-cap names, that gap places APLIF in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The APLIF insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads APLIF trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.5x leaves covenant headroom, the line to track on Appili Therapeutics Inc.'s next 10-Q.

APLIF fell 1.9% over the trailing 7 days, with a -21.9% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in APLIF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.